Article
Establishment of prognostic nomograms for predicting the progression free survival of EGFR-sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs.
Thoracic cancer - 1 May 2022
Du Xinyang, Bai Hua, Wang Zhijie, Daun Jianchun, Liu Zheng, Xu Jiachen, Chang Geyun, Zhu Yixiang, Wang Jie
Abstract excerpt
BACKGROUND: There is a lack of clinically available predictive models for patients with epidermal growth factor receptor (EGFR) mutation positive, advanced non-small cell lung cancer (NSCLC) treated with EGFR-tyrosine kinase inhibitors (TKIs). METHODS: The clinical data of patients at the Cancer Hospital, Chinese Academy of Medical Sciences between from January 2016 to January 2021 were retrospectively retrieved...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.